Bepirovirsen accepted for regulatory review in China as a potential first-in-class functional cure f

Bepirovirsen accepted for regulatory review in China as a potential first-in-class functional cure for chronic hepatitis B

Submission supported by statistically significant and clinically meaningful functional cure rates in pivotal Phase III B-Well trials